MEDICAGO
7.12.2020 13:32:51 CET | Business Wire | Press release
Medicago, a biopharmaceutical company headquartered in Quebec City, Canada, today announced Takashi Nagao as the company’s new President and Chief Executive Officer. Prior to becoming President and CEO, Mr. Nagao served as the Chairman of the Board of Medicago, where for the last four years, he has guided Medicago executives to get the company to where it is today.
Medicago, a research and development company for the last 20 years, is embarking on a transformative year, one that will see the company build on its R&D roots to become a company that also produces and commercializes vaccines and other immunotherapies. Mr. Nagao has extensive experience leading pharmaceutical companies through the pre-commercial and commercial process and is well positioned to ensure the successful launch of Medicago’s COVID-19 and influenza vaccines, subject to regulatory approvals. Mr. Nagao will continue Medicago’s evolution towards its goal of being a fully operational commercial entity, able to respond to the needs of the global public health community and medical authorities and professionals.
“Taking on this new role with Medicago during this exciting time is a great honour for me,” said Mr. Nagao, President and Chief Executive Officer, Medicago. “I want our employees, investors, and stakeholders such as the Government of Canada to know that I will put all my efforts into seeing our COVID-19 and influenza vaccines through to a successful launch to protect as many people as possible.”
From 2007 to 2017, Mr. Nagao oversaw the establishment of Mitsubishi Tanabe Pharma Corporation’s U.S. presence and led the team that successfully achieved NDA of RADICAVA®, the first FDA-approved drug in over 20 years for the patients with Amyotrophic Lateral Sclerosis (ALS). Prior to that, Mr. Nagao was a Managing Director in investment banking at J.P. Morgan and Deutsche Bank where he was responsible for global clients and leading equity and cross-border M&A transactions in the pharmaceutical and biotechnology sector in North America, Japan and Europe. He has an MBA from Harvard Business School.
Mr. Nagao succeeds Dr. Bruce D. Clark, who held the position of President and CEO of Medicago since 2017 and was instrumental in the development of Medicago’s COVID-19 vaccine candidate.
Medicago recently announced the start of Phase 2/3 clinical trial of its plant-derived VLP vaccine candidate for COVID-19 to evaluate its efficacy, safety, and immunogenicity, based on the positive Phase 1 results and subsequent allowance to advance to Phase 2/3 by the Canadian regulatory authorities. The company is also building a new facility in Quebec to increase Canada’s domestic capacity for manufacturing vaccines, producing up to a billion doses annually.
“Medicago is at an inflection point. We are moving from a research and development focused organization to become a commercial entity supplying vaccines to Canadians and people around the world,” said Mr. Nagao.
About Medicago
Medicago is a biopharmaceutical company and pioneer in plant-derived therapeutics. Founded in 1999 with the belief that innovative approaches and rigorous research would bring new solutions in healthcare.
Our mission is to improve global health outcomes by leveraging innovative plant-based technologies for rapid responses to emerging global healthcare challenges. Medicago is committed to advancing therapeutics against life-threatening diseases worldwide. Our team includes over 450 scientific experts and employees in Canada and the United States and academic affiliations in Europe and South Africa.
Medicago has previously demonstrated its capability to be a first responder in a flu pandemic. In 2009, the company produced a research-grade vaccine candidate against H1N1 in just 19 days. In 2012, Medicago manufactured 10 million doses of a monovalent influenza vaccine candidate within one month for the Defense Advanced Research Projects Agency (DARPA), part of the U.S. Department of Defense. In 2015, Medicago also demonstrated in principle that it could rapidly produce an anti-Ebola monoclonal antibody cocktail for the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services.
For more information: www.medicago.com
To learn more about our plant-based technology: Video / Website
View source version on businesswire.com: https://www.businesswire.com/news/home/20201204005409/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LogicMonitor Makes AI the Standard, Not the Upgrade4.11.2026 09:00:00 CET | Press release
New platform packages include Edwin AI and Digital Experience at every tier, uniting signals, context and governed action on one licensing model LogicMonitor®, the AI-first platform for Autonomous IT, today announced new platform packages that make Edwin AI and LogicMonitor Digital Experience, including Synthetics and Internet Sonar, standard in every tier. By bringing full digital experience and internet health visibility together with AI-driven operations in every package, LogicMonitor helps teams connect what users experience to the signals behind it and move toward a governed next step. AI is now essential to modern IT operations, yet too often, the capabilities needed to put it into practice remain fragmented across tools and licensing models. As enterprises move toward Autonomous IT, access to AI-driven intelligence and end-to-end visibility must become the foundation, not an added layer of complexity. “IT teams don't need more separate Observability tools with AI bolted on; they
AiDEN Auto and Volvo Trucks First to Offer Embedded E-Transportation Regulatory Compliance Through the Infotainment System4.11.2026 09:00:00 CET | Press release
An industry-first integration brings RO e-Trans compliance monitoring directly into the Volvo Trucks infotainment interface and Volvo Connect, making regulatory management easier, safer, and more efficient for drivers and fleets. AiDEN Auto, a pioneer in connected vehicle software solutions, has partnered with Volvo Trucks to integrate RO e-Trans regulatory compliance management directly into the truck's in-cab infotainment system and the Volvo Connect back-office portal. Made available through Volvo Trucks' suite of digital services and Volvo Connect ecosystem, this innovative application allows drivers and fleet managers to monitor and maintain compliance with Romania's mandatory national e-Transport regulations in real time—without leaving the cab or relying on secondary mobile devices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104342472/en/ AiDEN Auto, a pioneer in connected vehicle software solutions, has partne
Azerbaijan Signs its Participation Contract in Expo 2030 Riyadh4.11.2026 08:47:00 CET | Press release
The Republic of Azerbaijan has signed its Participation Contract in Expo 2030 Riyadh. The contract was signed by Talal Al-Marri, Chief Executive Officer of Expo 2030 Riyadh and H.E. Mr. Anar Alakbarov, Assistant to the President of the Republic of Azerbaijan, during a ceremony held in Baku, Azerbaijan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103050461/en/ The contract was signed by Talal Al-Marri, Chief Executive Officer of Expo 2030 Riyadh and H.E. Mr. Anar Alakbarov, Assistant to the President of the Republic of Azerbaijan, during a ceremony held in Baku, Azerbaijan. The signing marks an important milestone in Azerbaijan’s participation journey, allowing it to move from planning into delivery of its presence at Expo 2030 Riyadh. Holding the ceremony in Baku reflects the longstanding friendship between the Republic of Azerbaijan and the Kingdom of Saudi Arabia, as well as the importance Azerbaijan attaches to its
GN Corporation’s academic event NCRM NICHE commemorates 21st anniversary of NCRM.4.11.2026 07:10:00 CET | Press release
Kamineni Institute, Hyderabad wins XXI Fujio Cup Quiz on stem cells and regenerative medicine. The XXI edition of Fujio Cup Quiz (FCQ) in NCRM NICHE 2026, hosted by GN Corporation, Japan and Nichi-In centre for Regenerative Medicine (NCRM), was won by Sameer Kumar Reddy and Chava Aravind Kumar from Kamineni Academy of Medical Sciences and Research Centre, Hyderabad, India. Ganga Anand Desai and Amith Mathew from Sri Ramachandra Institute of Higher Education and Research, Chennai, India, came runners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103893272/en/ NCRM NICHE is held every year in October since 2006, past 21 years. In 2026, in the active knowledge gaining event, Fujio Cup Quiz, 80 teams from institutes of biotechnology, medicine, veterinary, dentistry and allied health sciences participated, among whom four got to the finals. Kamineni Academy of Medical Sciences, Hyderabad, India won the prestigious Fujio Cup.
Global Consumer Trends 2027: Trust, Transparency and Control Take Centre Stage4.11.2026 06:01:00 CET | Press release
Consumers are no longer placing full trust in brands, technology or the future itself. As uncertainty becomes a permanent feature of daily life, greater value is being placed on reliability, transparency and immediate proof of value. Euromonitor International's Top Global Consumer Trends 2027 report finds consumers seeking greater control as uncertainty reshapes consumer behaviour. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103010032/en/ Euromonitor's Top global consumer trends 2027 Drawing on insights from Passport, Euromonitor International's AI-powered market intelligence platform, the report finds consumers looking for balance and control in a world they no longer expect to be certain. Across markets, consumers are placing greater value on reliability, transparency, community and immediate, tangible benefits. “Consumers are no longer simply buying products or services; they're looking for confidence," said Ali Ang
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom